Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among patients hospitalized for HF, elevated plasma levels of NT-proBNP, MR-proADM, copeptin, and cystatin C are associated with higher mortality after discharge, whereas NT-proBNP is the only biomarker that predicts the risk of re-hospitalization due to cardiac causes.
|
31339668 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study population consisted of 1,504 individuals with no prior history of congestive heart failure or asymptomatic left ventricular ejection fraction ≤40% and an estimated glomerular filtration rate (eGFR) based on cystatin C >15 mL/min/1.73 m2.
|
31238302 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
After multivariable adjustment for clinical variables and renal and CV biomarkers (estimated glomerular filtration rate, cystatin-C, urine albumin-to-creatinine ratio, FGF-23, high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-reactive protein), low Klotho concentration remained strongly associated with increased risk of CV death or hospitalization for heart failure [adjusted hazard ratio (HR) 2.62; 95% confidence interval (CI) 1.35-5.08; P < 0.01].
|
30773798 |
2019 |
Congestive heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Higher CysC level showed a negative relation to survival and bone loss in males with CHF.
|
30820184 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
After multivariate adjustment, increasing concentration of Cys-C (per SD of log-transformed Cys-C) was significantly associated with a 28% higher hazard of CVD or heart failure hospitalization (hazard ratio [ HR ] 1.28, 95% confidence interval [ CI ] 1.12-1.46, P<0.001), including CVD ( HR 1.24, 95% CI 1.04-1.47, P=0.01) and heart failure hospitalization ( HR 1.42, 95% CI 1.19-1.69, P<0.001).
|
30371283 |
2018 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since only 60-70% of select patients with chronic heart failure (CHF) are responders in cardiac resynchronization therapy (CRT), this study aimed to investigate whether serum cystatin C (Cys C) can be used to evaluate the effectiveness of CRT in patients with CHF.
|
29478109 |
2018 |
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Spironolactone up-titration was associated with lower risk of HF hospitalization or death in patients with high cystatin C (CysC) (interaction, <i>P</i> = 0.021).
|
29896315 |
2018 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk.
|
30427997 |
2018 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the predictive value of single and repeated measurements of GDF-15 compared to Cystatin C and CRP for incidence of heart failure (HF) and death due to coronary heart disease (CHD) in the general population.
|
29771963 |
2018 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated baseline cystatin C, as a biomarker of renal dysfunction, is associated with reduced diuretic response during heart failure hospitalization.
|
29482026 |
2018 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three hypotheses were tested: (1) higher levels of high-sensitivity cardiac troponin T, N-terminal of prohormone brain natriuretic peptide, and cystatin C predict risk of death, cardiovascular disease, HF, and dementia; (2) higher levels of cardiovascular disease biomarkers are associated with increased risk of HF and then secondary increased risk of dementia; and (3) risk of dementia is lower among participants with a combination of lower coronary artery calcium, atherosclerosis, and lower high-sensitivity cardiac troponin T (myocardial injury).
|
28735291 |
2017 |
Congestive heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, in multivariable regression analysis Cystatin C predicted mortality after the adjustment for baseline renal function, AKI, BNP levels and heart failure risk factors.
|
28756070 |
2017 |
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariable predictors of T2MI were older age, lower systolic blood pressure, history of coronary artery disease, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, nitrate use, and elevated concentrations of glucose, N-terminal pro-B type natriuretic peptide, and cystatin C. Patients with T2MI had higher rates of subsequent adverse events than those without T2MI (per 100 person-years: MACE, 53.7 versus 21.1, P<0.001; all-cause death, 23.3 versus 3.3, P<0.001; cardiovascular death, 17.5 versus 2.6, P<0.001; heart failure events, 22.4 versus 7.4, P<0.001); these rates are similar to those seen in patients with type 1 MI.
|
27881568 |
2017 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study indicates that cystatin C-based eGFR and albuminuria are better predictors for risk of heart failure compared to creatinine-based eGFR.
|
28515118 |
2017 |
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We used the common variant rs911119 in CST3 as an instrumental variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, ischemic stroke, and heart failure.
|
27561768 |
2016 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals.
|
19808324 |
2009 |